Chong Kun Dang Pharmaceutical Corp
185750
Company Profile
Business description
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).
Contact
368 Chungjungro-3Ga
Seodaemun-gu
Seoul120-756
KORT: +82 221940300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
2,347
Stocks News & Analysis
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
stocks
Alphabet earnings: Strong AI monetization continues to spearhead results
We maintain our fair value estimate for wide-moat Alphabet.
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,935.30 | 38.90 | -0.43% |
| CAC 40 | 8,299.09 | 138.80 | -1.64% |
| DAX 40 | 24,763.12 | 392.29 | -1.56% |
| Dow JONES (US) | 51,711.65 | 506.93 | -0.97% |
| FTSE 100 | 10,639.17 | 77.80 | -0.73% |
| HKSE | 24,901.62 | 309.19 | -1.23% |
| NASDAQ | 25,137.69 | 553.21 | -2.15% |
| Nikkei 225 | 64,426.44 | 1,996.16 | -3.01% |
| NZX 50 Index | 13,770.39 | 24.92 | -0.18% |
| S&P 500 | 7,408.30 | 90.66 | -1.21% |
| S&P/ASX 200 | 8,765.30 | 30.40 | -0.35% |
| SSE Composite Index | 3,833.56 | 43.22 | -1.11% |